STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2636 by analyst upside · 2026-08-12
GILD
Gilead Sciences, Inc.
Healthcare · Market Cap $168B · P/E 0x
ANALYST PRICE TARGET
+15.9%
implied upside to consensus target
Current Price $135.77
Consensus Target $157.41
Bull Target $180.0
Bear Target $123.0
Analysts Covering 27
ANALYST CONSENSUS - BUY
Strong Buy
6
Buy
15
Hold
7
Sell
0
52-Week Low $108.46
52-Week High $157.29
YTD Return +13.0%
FUNDAMENTALS
Market Cap $168B
P/E Ratio (TTM) N/A
Forward P/E 13.8x
EPS (TTM) $-2.65
PEG Ratio 2.14
Dividend Yield 2.47%
Revenue (TTM) $30.5B
Profit Margin -10.6%
52-WEEK RANGE
52-Week Low $108.46
52-Week High $157.29
Current Price $135.77
Bear Target $123.0
Bull Target $180.0
● Now $135.77 ● Target $157.41
TRADING DATA
Avg Volume 7.8M
YTD Return +13.0%
Analyst Count 27
Consensus Buy
Upside to Target +15.9%
Last Updated 2026-08-12

ANALYST SUMMARY

Gilead Sciences, Inc. (GILD) is currently trading at $135.77 with a Wall Street consensus price target of $157.41, implying potential upside of 15.9% over the next 12 months. 27 analysts currently cover GILD, with a consensus rating of Buy - 75% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $180.0, while the most cautious has a target of $123.0.

GILD operates in the Healthcare sector with a market capitalisation of $168B. The stock is up 13.0% year-to-date and is currently trading near the upper end of its 52-week range of $108.46 – $157.29.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for GILD, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Cantor Fitzgerald reit
Overweight → Overweight 2026-06-16 40% win rate (10 calls)
Maxim Group ↑ Upgrade
Hold → Buy 2026-05-20 28% win rate (40 calls)
Truist Securities reit
Buy → Buy 2026-05-08 Building track record
RBC Capital - Reiterated
Sector Perform → Sector Perform 2026-05-08 Building track record
Citigroup - Reiterated
Buy → Buy 2026-04-13 Building track record
Morgan Stanley - Reiterated
Overweight → Overweight 2026-04-10 Building track record
Jefferies ● Initiated
Buy 2026-03-10 50% win rate (6 calls)
Needham reit
Buy → Buy 2026-02-23 20% win rate (5 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
61
out of 100
Coverage depth
25/30
Consensus clarity
22/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →